T2 Biomarker 221 237 ipilimumab-naive
T3 Condition 933 938 tumor
T4 Level 978 991 T cell clones
T5 Organism 884 892 patients
T6 Protein 928 944 intratumoral TCR
T7 Biomarker 202 212 ipilimumab
T8 Biomarker 221 231 ipilimumab
T9 Gene 352 370 or T cell receptor
T10 Gene 117 124 genomic
T11 Condition 136 141 tumor
T12 Protein 372 375 TCR
T13 Condition 296 302 Tumors
T14 Condition 486 498 intratumoral
T15 Condition 578 584 tumors
T16 Condition 413 421 mutation
T17 Biomarker 1099 1108 nivolumab
T18 Biomarker 256 265 nivolumab
T19 Condition 174 182 melanoma
T20 Biomarker 616 626 neoantigen
T21 Condition 136 142 tumors
T22 Condition 928 940 intratumoral
T23 Condition 61 66 tumor
T24 Organism 151 159 patients
T25 Level 741 760 immune cell subsets
T26 Condition 629 637 mutation
T27 Gene 831 854 immune checkpoint genes
T28 Gene 1041 1048 genomic
T29 Condition 578 583 tumor
T30 Biomarker 1010 1020 neoantigen
T31 Organism 403 411 patients
T32 Biomarker 426 436 neoantigen
T33 Condition 491 496 tumor
T34 Biomarker 692 701 nivolumab
T35 Condition 629 638 mutations
R1 Relation Arg1:T11 Arg2:T24
R2 Relation Arg1:T21 Arg2:T24
